https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-01 / Expert Rev Vaccines 2011 Oct;10(10):1355-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-01 / Expert Rev Vaccines 2011 Oct;10(10):1355-72011-10-01 00:00:002019-02-15 08:53:13Proving the principle: dendritic cell-based vaccines in urogenital cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-08-08 / J. Clin. Oncol. 2011 Sep;29(27):3677-85
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-08-08 / J. Clin. Oncol. 2011 Sep;29(27):3677-852011-08-08 00:00:002019-02-15 08:52:48Immunotherapy for prostate cancer: biology and therapeutic approaches
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-07-31 / J Clin Oncol 29: 2011 (suppl 7; abstr 176)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-07-31 / J Clin Oncol 29: 2011 (suppl 7; abstr 176)2011-07-31 11:54:532019-09-30 09:54:03Antigen-specific immunity and tumor inflammation after vaccination with BPX-101, a drug-activated dendritic cell vaccine for metastatic castration-resistant prostate cancer (mCRPC).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-23 / Clin. Cancer Res. 2011 Aug;17(16):5233-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-23 / Clin. Cancer Res. 2011 Aug;17(16):5233-82011-06-23 00:00:002019-02-15 08:52:51Prostate cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-15 / J Cancer 2011;2:357-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-15 / J Cancer 2011;2:357-92011-06-15 00:00:002019-02-15 08:52:49Sipuleucel-T: autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-15 / Expert Opin Biol Ther 2011 Aug;11(8):997-1009
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-15 / Expert Opin Biol Ther 2011 Aug;11(8):997-10092011-06-15 00:00:002019-02-15 08:52:50Recent advances in immunotherapy for the treatment of prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-15 / Clin. Cancer Res. 2011 Jun;17(12):3884-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-15 / Clin. Cancer Res. 2011 Jun;17(12):3884-912011-06-15 00:00:002019-02-15 08:52:52Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-05 / J Clin Oncol 29: 2011 (suppl; abstr 4670)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-05 / J Clin Oncol 29: 2011 (suppl; abstr 4670)2011-06-05 00:00:002011-06-05 00:00:00Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-05-24 / Nat Rev Clin Oncol 2011 May;8(9):551-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-05-24 / Nat Rev Clin Oncol 2011 May;8(9):551-612011-05-24 00:00:002019-02-15 08:53:07Immunotherapy for the treatment of prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-05-10 / Clin. Cancer Res. 2011 Jul;17(13):4558-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-05-10 / Clin. Cancer Res. 2011 Jul;17(13):4558-672011-05-10 00:00:002019-02-15 08:52:51Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer
